127 related articles for article (PubMed ID: 35482266)
21. National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
Dottino JA; He W; Sun CC; Zhao H; Fu S; Rauh-Hain JA; Suidan RS; Lu KH; Giordano SH; Meyer LA
Int J Gynecol Cancer; 2020 Aug; 30(8):1195-1202. PubMed ID: 32616627
[TBL] [Abstract][Full Text] [Related]
22. Cytoreductive Surgery for Relapsed Ovarian Cancer.
Meirson T; Bomze D; Markel G
N Engl J Med; 2022 Mar; 386(9):896-897. PubMed ID: 35235735
[No Abstract] [Full Text] [Related]
23. Time to Evolve Terminology from "Debulking" to Cytoreductive Surgery (CRS) in Ovarian Cancer.
Brennan DJ; Moran BJ
Ann Surg Oncol; 2021 Oct; 28(11):5805-5807. PubMed ID: 34304313
[No Abstract] [Full Text] [Related]
24. Cytoreductive Surgery for Relapsed Ovarian Cancer. Reply.
Harter P; Reuss A; du Bois A
N Engl J Med; 2022 Mar; 386(9):897. PubMed ID: 35235736
[No Abstract] [Full Text] [Related]
25. The effects of neutral argon plasma versus electrocoagulation on tissue in advanced-stage ovarian cancer: a case series.
Nieuwenhuyzen-de Boer GM; van de Berg NJ; Gao XS; Ewing-Graham PC; van Beekhuizen HJ
J Ovarian Res; 2022 Dec; 15(1):140. PubMed ID: 36581854
[TBL] [Abstract][Full Text] [Related]
26. Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
Harrison R; Zighelboim I; Cloven NG; Marcus JZ; Coleman RL; Karam A
Gynecol Oncol; 2021 Dec; 163(3):448-452. PubMed ID: 34686355
[No Abstract] [Full Text] [Related]
27. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic Resection as Part of Cytoreductive Surgery in Advanced-stage and Recurrent Epithelial Ovarian Cancer--A Single-center Experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Jul; 35(7):4125-9. PubMed ID: 26124365
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
30. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
[TBL] [Abstract][Full Text] [Related]
31. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
Turnbull HL; Akrivos N; Wemyss-Holden S; Maiya B; Duncan TJ; Nieto JJ; Burbos N
Arch Gynecol Obstet; 2017 Mar; 295(3):681-687. PubMed ID: 27995370
[TBL] [Abstract][Full Text] [Related]
32. When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M; Harter P; Heitz F; du Bois A
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):493-497. PubMed ID: 29743148
[TBL] [Abstract][Full Text] [Related]
33. In Reference to Jonsdottir B et al. "The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer".
Carboni F; Valle M
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):956-957. PubMed ID: 32748149
[No Abstract] [Full Text] [Related]
34. [Progress in preoperative evaluation methods regarding cytoreduction in patients with advanced ovarian cancer].
Liu J; Zhang K
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Jul; 42(7):854-859. PubMed ID: 28845013
[TBL] [Abstract][Full Text] [Related]
35. Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control.
Petrillo M; Anchora LP; Scambia G; Fagotti A
Oncologist; 2016 May; 21(5):532-4. PubMed ID: 27009941
[TBL] [Abstract][Full Text] [Related]
36. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
Fan XM; Zhang J; Niu SH; Li KX; Song CZ
Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
[TBL] [Abstract][Full Text] [Related]
37. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
38. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
Cordeiro Vidal G; Babin G; Querleu D; Guyon F
Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
[TBL] [Abstract][Full Text] [Related]
39. Minimally Invasive Secondary Cytoreductive Surgery for Superficial Celiac and Cardio-Phrenic Isolated Nodal Recurrence of Ovarian Cancer.
Loverro M; Ergasti R; Conte C; Gallitelli V; Nachira D; Scaglione G; Fagotti A; Scambia G; Gallotta V
Ann Surg Oncol; 2022 Apr; 29(4):2603-2604. PubMed ID: 35000090
[No Abstract] [Full Text] [Related]
40. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
